ArticleFrontiers in oncology2026
Immune checkpoint inhibition in
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroesophageal adenocarcinoma (GEA) represents a heterogenous disease with poor prognosis, in which biomarker-driven strategies have gained relevance to optimize treatment selection. Epstein-Barr virus positive GEA (EBV-GEA) is an immune-enriched molecular subtype defined by TCGA suggested to have potential sensitivity to immune checkpoint inhibitors. However, clinical evidence supporting the efficacy of immunotherapy in this subgroup remains limited, and EBV testing is not yet considered a validated biomarker in international clinical guidelines. We report a case of a 74-year-old male with locally advanced, HER-2 negative, mismatch repair-proficient, EBV-positive gastric adenocarcinoma, with high PD-L1 expression (CPS 69), who experienced disease progression during perioperative FLOT chemotherapy. The patient subsequently received first-line treatment with nivolumab plus FOLFOX, achieving a marked radiological response. Salvage surgery revealed a complete pathological response and no further treatment with nivolumab was administered after surgery. This case illustrates the potential benefit of immunotherapy in EBV-positive gastric cancer, even in the microsatellite-stable setting. The overlap of biomarkers in this patient may have contributed to immune response, highlighting the importance of comprehensive molecular profiling in GEA and supporting EBV status as a promising predictor of immunotherapy benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.